ArticleInternational journal of geriatric psychiatry2025
Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database.
Article in International journal of geriatric psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies.Journal of personalized medicine · 2026Review
- Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database.International journal of geriatric psychiatry · 2025Article
- Real-world analysis of gender differences in drug-induced insomnia: evidence from FAERS and CVARDD databases.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesWhile the risks of antipsychotics in older adults are well recognized, clinical trials often exclude frail older patients, have short follow-up periods, and provide limited comparative data on specific drugs. This study aimed to explore age-related differences in the adverse effects of six commonly prescribed antipsychotics using a pharmacovigilance database, with additional analysis of sex-based variations.
methodsWe analyzed adverse event (AE) reports associated with aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and haloperidol from the FDA Adverse Event Reporting System (FAERS) database between Q4 2003 and Q2 2024. We utilized Standardized MedDRA Queries (SMQs) and self-defined queries to categorize 18 groups of AEs. Adjusted logistic regression was employed to calculate adjusted reporting odds ratios (aRORs) with 95% confidence intervals (CIs).
resultsOur analysis revealed substance-specific differences in AE profiles. Risperidone had the highest aROR for hyperprolactinemia (aROR 212, 95% CI 203-221), haloperidol for dystonia (aROR 46, 95% CI 41-51), and aripiprazole for akathisia (aROR 45, 95% CI 42-49). Patients aged 65 and older generally demonstrated a higher likelihood of experiencing cardiac, extrapyramidal motor, and sedative AEs compared to those under 65, with few exceptions across the drugs investigated. In contrast, younger patients showed higher odds for metabolic AEs, including dyslipidemia and hyperglycemia (associated with olanzapine and quetiapine), as well as weight gain (with olanzapine, quetiapine, risperidone, and haloperidol). With few exceptions, women generally showed higher reporting odds of adverse events. Sex-related differences were especially pronounced for hyperprolactinemia, with 4.7-8.0 times higher reporting odds in women for aripiprazole, olanzapine, quetiapine, and haloperidol-except for risperidone, where a post-2014 rise in male reports led to higher odds in men. Risperidone was also associated with increased reporting odds of weight gain in men. Additionally, aripiprazole and olanzapine showed 3 to 6 times higher reporting odds for anticholinergic syndrome in men compared to women.
conclusionsIt is essential to consider both age and sex in treatment decisions to optimize the efficacy and tolerability of antipsychotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.